Plasma glucagon and cortisol levels were determined in pigs during ethanol-induced hypoglycemia. This hypoglycemia is due to an inhibition of gluconeogenesis which could be related to an abnormal secretion of gluconeogenetic hormones. In six pigs the infusion of ethanol for seven hours (6 mg/kg/min) induced a significant decrease of plasma glucose which was associated with a significant increase of plasma glucagon in the portal vein, femoral artery and hepatic vein. Corresponding with the period of maximal hypoglycemia, plasma cortisol in the femoral artery was also significantly increased. On the other hand, plasma insulin levels were consistently reduced during hypoglycemia. In a second group of six pigs ethanol was infused along with a glucose infusion (3 mg/kg/min) in order to obtain a relatively constant glucose concentration. In this group ethanol did not produce any significant modification of plasma glucagon and cortisol. Therefore, glucagon and cortisol hypersecretion is related to hypoglycemia induced by ethanol. Both the increase in plasma glucagon and cortisol and the decrease in plasma insulin could represent a protective mechanism against alcohol-hypoglycemia.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Glucagon, rather than Glucagon-Like Peptide 1, Mediates Higher Post-Lunch Glucose Excursions during Breakfast Skipping in Asian Indian Patients with Uncontrolled Type 2 Diabetes Mellitus.
Indian J Endocrinol Metab
December 2024
Department of Endocrinology, Bai Yamunabai Laxman Nair Charitable Hospital and Topiwala National Medical College, Mumbai, Maharashtra, India.
Introduction: The effect and mechanism of skipping breakfast on glycemic control in type 2 diabetes mellitus (T2DM) in Asian-Indians is unknown.
Methods: Cross-over, within-group study recruiting 5 habitual breakfast eaters (BE) and 5 habitual breakfast skippers (BS) with uncontrolled T2DM (HbA1c 7-9%). Patients underwent testing after three days of following their usual breakfast habits and after seven days of crossing over to the other arm.
Cotadutide reversible self-assembly based long-acting injectable depot for sustained delivery of GLP-1 glucagon receptor agonists with controlled burst release.
J Control Release
January 2025
Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Waltham, MA, USA.
Cota is a lipidated dual GLP-1 and Glucagon receptor agonist that was investigated for the treatment of various metabolic diseases, it is designed for once daily subcutaneous administration. Invasive daily injections often result in poor patient compliance with chronic disease, and here, we demonstrate an innovative strategy of encapsulating reversible cota self-assembled fibers within an in-situ forming depot of low molecular weight poly(lactic-co-glycolic) acid (LWPLGA) for sustained delivery GLP-1 and Glucagon receptor agonist with controlled burst release. This could be a suitable alternative to other sustained delivery strategies for fibrillating peptides.
View Article and Find Full Text PDFDetection of Insulin in Insulin-Deficient Islets of Patients with Type 1 Diabetes.
Life (Basel)
January 2025
Laboratory of Nervous System Development, Avtsyn Research Institute of Human Morphology of Federal State Budgetary Scientific Institution "Petrovsky National Research Centre of Surgery", Tsurupi Street, 3, 117418 Moscow, Russia.
Type 1 diabetes (T1D) is related to the autoimmune destruction of β-cells, leading to their almost complete absence in patients with longstanding T1D. However, endogenous insulin secretion persists in such patients as evidenced by the measurement of plasma C-peptide. Recently, a low level of insulin has been found in non-β islet cells of patients with longstanding T1D, indicating that other islet cell types may contribute to persistent insulin secretion.
View Article and Find Full Text PDFEarly Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.
Infect Dis Rep
January 2025
Royal Brompton Hospital, Part of GSTT NHS Foundation Trust, London SW3 6NP, UK.
Background: Glucagon-like peptide-1 (GLP-1) agonists are an existing treatment option for patients with insulin-resistant states, which elicit further pleiotropic effects related to immune cell recruitment and vascular inflammation. GLP-1 agonists downregulate the cluster of differentiation 147 (CD147) receptor, one of several receptors for the SARS-CoV-2 spike protein that mediate viral infection of host cells.
Methods: We conducted an open-label prospective safety and tolerability study including biomarker responses of the GLP-1 agonist Liraglutide, administered for 5 days as an add-on therapy to the standard of care within 48 h of presentation in a cohort of 13 patients hospitalized with COVID-19 pneumonia.
Engineering a high-throughput clone for industrial-scale production of long-acting GLP-1 analogue with retained bio-efficacy.
Biotechnol Prog
January 2025
Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu, India.
Type 2 diabetes mellitus (T2DM) and obesity are critical global health issues with rising incidence rates. Glucagon-like peptide-1 (GLP-1) analogues have emerged as effective treatments due to their ability to regulate blood glucose levels and gastric emptying through central nervous signals involving hypothalamic receptors, such as leptin. To address the short plasma half-life of native GLP-1, a C-16 fatty acid was conjugated to lysine in the GLP-1 analogue sequence to enhance its longevity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!